MabionCD20
Product Description
Mabion SA
-
PL
-
2023On CPHI since
-
3Certificates
-
250 - 499Employees
Company types
Primary activities
Categories
Mabion SA
-
PL
-
2023On CPHI since
-
3Certificates
-
250 - 499Employees
Company types
Primary activities
Mabion SA resources (2)
-
News Mabion signs contract to purchase new bioreactors, diversifies technology, and opens to new customers
On July 11th, 2023, Mabion concluded an agreement with Global Life Sciences Solutions Polands Sp. z o.o., a Cytiva group company for the purchase of a set of Xcellerex XDR bioreactors with conventional mixing technology. The contract is valued at EUR 3.2 million.The vendor will manufacture and install a set of bioreactors in Mabion's facility in Konstantynów Łódzki, Poland, delivery of which is scheduled for Q3 2023, followed by installation, commissioning, qualification testing and acceptance of the equipment. The Xcellerex XDR bioreactor suite is based on technology using a conventional mixing system, as opposed to Mabion's current orbital shaking technology, which will allow the Company to achieve technological diversification, as outlined in the 2023-2027 Strategy in earlier this year. -
Brochure Mabion - Your Biologics CDMO
A presentation including a demonstration of Mabion's capabilities as a biologics CDMO.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance